| Online: | |
| Visits: | |
| Stories: |
| Story Views | |
| Now: | |
| Last Hour: | |
| Last 24 Hours: | |
| Total: | |
Profiting off Fear- Drug Company Stocks Exploding After Ebola Identified in America
An unrelenting, ravenous greed looks to capitalize on the emergence of pandemic disease coming to America. Investors are beginning to push and shove for drug company stocks that have exploded since Ebola was first identified in America. It’s almost as if vultures have begun to circle overhead in Dallas, Texas, the site of the first Ebola diagnosis on American soil. Investors are lining up to make a profit off the pharmaceutical machine that’s hunched over and ready to pounce.
The following five lucrative stocks are a glaring example of how greed is perpetuating disease in the universe today. Notice how four of the five stocks are of different pharmaceutical companies which are poised to compete for millions by selling their version of an Ebola drug. These fast-tracked drugs will only be used to manage the disease year after year, bringing a return on investments. The actual immune-syste-empowering approaches for saving lives (like this one) are suppressed, because they don’t fit into the profitable model of healthcare that has taken over the world.
#1 Tekmira Pharmaceuticals (TKMR) is exploding in popularity, establishing itself as the most lucrative Ebola stock. Their TKM-Ebola drug was fast-tracked through the FDA in August, bypassing long-term safety studies and FDA oversight as if it was already poised to capitalize on the West African Ebola epidemic that continues to expand. The company, worth about $470 million, has been “swinging by double digits” as Ebola news ripples through the media. The stock recently shot up 18% on Wednesday, propping itself up a whopping 180% since mid-July.
#2 BioCryst Pharmacuticals (BCRX) is another of the more established pharmaceutical research companies booming right along with the Ebola news headlines, valued at about $720 million. BioCryst is engaged in research for an Ebola drug of its own. As investors continue to speculate on this stock, company executives are rushing to get a drug ready to market.
#3 Sarepta Therapeutics (SRPT) has its nose to the grindstone too, researching for profitable Ebola drugs. This company has the help of the US military. Remember, the US CDC owns a patent on Ebola, so there’s much more at stake in all this disease mongering; the CDC could be in on the royalties. SRPT is valued at $900 million and is key biotech stock to watch out for as Ebola rears its head in the land of the free.
Source:
